TimesSquare Capital Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

TimesSquare Capital Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-344,580	Closed	-$35.1M	–	182
2023 Q2	$35.1M	Buy	344,580 +341,180	+10,035%	+$32.3M	0.5%	84
2023 Q1	$309K	Buy	+3,400	New	+$200K	﹤0.01%	176
2020 Q3	–	Sell	-355,900	Closed	-$55.5M	–	250
2020 Q2	$55.5M	Buy	355,900 +145,000	+69%	+$22M	0.53%	76
2020 Q1	$30.4M	Buy	+210,900	New	+$40.7M	0.36%	123

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

TimesSquare Capital Management's RETA Position: Q3 2023 in Review

TimesSquare Capital Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 344,580 shares — an estimated $35.1M sold.

TimesSquare Capital Management first reported a position in RETA in Q1 2020 and held it in 4 quarters. The position peaked at $55.5M in Q2 2020. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

TimesSquare Capital Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
TimesSquare Capital Management sold 344,580 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $35.1M.
TimesSquare Capital Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2020 and held it in 4 quarters.
TimesSquare Capital Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $55.5M in Q2 2020.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on TimesSquare Capital Management's 13F filing for Q3 2023, filed 17 Nov 2023.